Demand for Bacteriophage to Expand at a CAGR of Over 4% Through 2030 | Life Extension, Arthur Andrew Medical, BioChimpharm

Emergence of multi-drug-resistant pathogens, as a result of huge application of antibiotics over a long time, is growing, and becoming increasingly difficult to treat.

Click here to Get Complete Synopsis of the Report – https://www.factmr.com/report/bacteriophage-market

Bacteriophage technologies have therefore begun to garner great interest as alternatives to antibiotics. Rising prevalence of antimicrobial resistance and limited new antibiotic discoveries and development have sustained innovation and led to a renewal of interest in bacteriophages.
Advantages of phage therapy along with probiotics are gaining importance in the treatment of antibacterial-resistant infections, and demand is expected to grow over the next few years.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5558

Currently, players operating in the bacteriophage market are concentrating on meeting the needs of health professionals and patients by introducing novel phage therapies, and are investing in the development of advanced bacteriophage platforms.

As per Fact.MR’s analysis, the global bacteriophage market was valued at around US$ 39 Mn in 2019, and is projected to expand at a CAGR of over 4% through 2030.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=5558

Key Takeaways from Bacteriophage Market Study

• Phage probiotics to account for over 95% market share in 2020.
• Gastroenterology is the most lucrative application segment, and holds nearly 94% of the market share.
• North America and Europe collectively hold over tow-third of the global market share, owing to technological advancements and increasing research & development activities across these regions.
• Retail and hospital pharmacies to account for over 80% value share through 2030.

For in-depth competitive analysis, buy now - https://www.factmr.com/checkout/5558

• The COVID19 pandemic has resulted in a temporary pause of all non-essential and elective procedures. Pharmaceutical manufacturers have been severely impacted, with companies reporting a significant drop in revenue due to supply chain crisis.
• Russia holds a major share in the European market, and is projected to expand at a CAGR of close to 6% over the next ten years.
• The U.S. has a leading share in North America, and is projected to expand at a modest CAGR of over 3% through 2030.

“Rising adoption of e-Commerce and increasing technological advancements in the development of phages are factors anticipated to aid growth of the global bacteriophage market over the coming years,” says a Fact.MR analyst.

Read More Trending and Similar Reports from Fact.MR – https://www.prnewswire.com/news-releases/blood-collection-tubes-for-liquid-biopsy-sales-set-to-grow-at-12-through-2021-factmr-301245568.html

Key Market Segments

Product
• Phage Probiotics
• Phage Therapeutics

Route of Administration
• Oral
• Topical
• Others

Application
• Gastroenterology
• Respiratory Infection Treatment
• Skin Infection Treatment
• Wound Prophylaxis
• Urogenital Infection Treatment
• Others

Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Region
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa

For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=5558

Strategic Partnerships and Funding by Manufacturers for Development of Phage Therapeutics

Pharmaceutical companies are collaborating with a collective goal to foster innovation by working with biotech firms and companies, governments, and market stakeholders, to enable supportable investments into a novel pipeline of bacteriophage therapy.

For instance, Janssen Pharmaceuticals, Inc. and Locus Biosciences Inc., in 2019, signed a complete license and collaboration agreement to manufacture, develop, and commercialize CRISPR-Cas3-enhanced bacteriophage (crPhage) products for the treatment of various infections, such as respiratory tract infection caused by two key pathogens, and other related infections. For this, Locus will receive US$ 20 million as an initial payment, which is expected to reach US$ 798 million from future sales of the product.
Such partnerships between pharmaceutical companies are aimed at strengthening and accelerating phage therapy development to introduce new therapies by end of this decade.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Content Source: https://www.factmr.com/media-release/1836/global-bacteriophage-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.